Literature DB >> 26030178

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Miguel Vizoso1, Humberto J Ferreira1, Paula Lopez-Serra1, F Javier Carmona1, Anna Martínez-Cardús1, Maria Romina Girotti2, Alberto Villanueva3, Sonia Guil1, Catia Moutinho1, Julia Liz1, Anna Portela1, Holger Heyn1, Sebastian Moran1, August Vidal4, Maria Martinez-Iniesta3, Jose L Manzano5, Maria Teresa Fernandez-Figueras6, Elena Elez7, Eva Muñoz-Couselo7, Rafael Botella-Estrada8, Alfonso Berrocal9, Fredrik Pontén10, Joost van den Oord11, William M Gallagher12, Dennie T Frederick13, Keith T Flaherty13, Ultan McDermott14, Paul Lorigan15, Richard Marais2, Manel Esteller16.   

Abstract

Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize. Here we study the contribution of epigenetic changes to the dissemination process by analyzing the changes that occur at the DNA methylation level between primary cancer cells and metastases. We found a hypomethylation event that reactivates a cryptic transcript of the Rab GTPase activating protein TBC1D16 (TBC1D16-47 kDa; referred to hereafter as TBC1D16-47KD) to be a characteristic feature of the metastatic cascade. This short isoform of TBC1D16 exacerbates melanoma growth and metastasis both in vitro and in vivo. By combining immunoprecipitation and mass spectrometry, we identified RAB5C as a new TBC1D16 target and showed that it regulates EGFR in melanoma cells. We also found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26030178      PMCID: PMC4968631          DOI: 10.1038/nm.3863

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  44 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  A CIOMS ethical code for animal experimentation.

Authors:  N Howard-Jones
Journal:  WHO Chron       Date:  1985

5.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer.

Authors:  Gary C Hon; R David Hawkins; Otavia L Caballero; Christine Lo; Ryan Lister; Mattia Pelizzola; Armand Valsesia; Zhen Ye; Samantha Kuan; Lee E Edsall; Anamaria Aranha Camargo; Brian J Stevenson; Joseph R Ecker; Vineet Bafna; Robert L Strausberg; Andrew J Simpson; Bing Ren
Journal:  Genome Res       Date:  2011-12-07       Impact factor: 9.043

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

Review 8.  DNA methylation profiling in the clinic: applications and challenges.

Authors:  Holger Heyn; Manel Esteller
Journal:  Nat Rev Genet       Date:  2012-09-04       Impact factor: 53.242

9.  Increased methylation variation in epigenetic domains across cancer types.

Authors:  Kasper Daniel Hansen; Winston Timp; Héctor Corrada Bravo; Sarven Sabunciyan; Benjamin Langmead; Oliver G McDonald; Bo Wen; Hao Wu; Yun Liu; Dinh Diep; Eirikur Briem; Kun Zhang; Rafael A Irizarry; Andrew P Feinberg
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

Review 10.  Epidemiology of invasive cutaneous melanoma.

Authors:  R M MacKie; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more
  42 in total

1.  Rab5C enhances resistance to ionizing radiation in rectal cancer.

Authors:  Antuani Rafael Baptistella; Michele Christine Landemberger; Marcos Vinicios Salles Dias; Fernanda Salgueiredo Giudice; Bruna Roz Rodrigues; Petrus Paulo Combas Eufrazio da Silva; Edson Kuatelela Cassinela; Tonielli Cristina Lacerda; Fabio Albuquerque Marchi; Adriana Franco Paes Leme; Maria Dirlei Begnami; Samuel Aguiar; Vilma Regina Martins
Journal:  J Mol Med (Berl)       Date:  2019-04-09       Impact factor: 4.599

2.  Disruption of Robo2-Baiap2 integrated signaling drives cystic disease.

Authors:  Qinggang Li; Shaoyuan Cui; Qian Ma; Ying Liu; Hongyu Yu; GuangRui Geng; Ewud Agborbesong; Chongyu Ren; Kai Wei; Yingjie Zhang; Jurong Yang; Xueyuan Bai; Guangyan Cai; Yuansheng Xie; Xiaogang Li; Xiangmei Chen
Journal:  JCI Insight       Date:  2019-09-19

Review 3.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

4.  DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats.

Authors:  David Brocks; Christopher R Schmidt; Michael Daskalakis; Hyo Sik Jang; Nakul M Shah; Daofeng Li; Jing Li; Bo Zhang; Yiran Hou; Sara Laudato; Daniel B Lipka; Johanna Schott; Holger Bierhoff; Yassen Assenov; Monika Helf; Alzbeta Ressnerova; Md Saiful Islam; Anders M Lindroth; Simon Haas; Marieke Essers; Charles D Imbusch; Benedikt Brors; Ina Oehme; Olaf Witt; Michael Lübbert; Jan-Philipp Mallm; Karsten Rippe; Rainer Will; Dieter Weichenhan; Georg Stoecklin; Clarissa Gerhäuser; Christopher C Oakes; Ting Wang; Christoph Plass
Journal:  Nat Genet       Date:  2017-06-12       Impact factor: 38.330

5.  A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.

Authors:  Ming Huang; Tianyu F Qi; Lin Li; Gao Zhang; Yinsheng Wang
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

6.  A non-coding function of TYRP1 mRNA promotes melanoma growth.

Authors:  David Gilot; Mélodie Migault; Laura Bachelot; Fabrice Journé; Aljosja Rogiers; Emmanuelle Donnou-Fournet; Ariane Mogha; Nicolas Mouchet; Marie-Laure Pinel-Marie; Bernard Mari; Tristan Montier; Sébastien Corre; Arthur Gautron; Florian Rambow; Petra El Hajj; Rania Ben Jouira; Sophie Tartare-Deckert; Jean-Christophe Marine; Brice Felden; Ghanem Ghanem; Marie-Dominique Galibert
Journal:  Nat Cell Biol       Date:  2017-10-09       Impact factor: 28.824

Review 7.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

Review 8.  Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance.

Authors:  Anna Martinez-Cardús; Miguel Vizoso; Sebastian Moran; Jose Luis Manzano
Journal:  Ann Transl Med       Date:  2015-09

9.  Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer.

Authors:  Angel Diaz-Lagares; Ana B Crujeiras; Paula Lopez-Serra; Marta Soler; Fernando Setien; Ashish Goyal; Juan Sandoval; Yutaka Hashimoto; Anna Martinez-Cardús; Antonio Gomez; Holger Heyn; Catia Moutinho; Jesús Espada; August Vidal; Maria Paúles; Maica Galán; Núria Sala; Yoshimitsu Akiyama; María Martínez-Iniesta; Lourdes Farré; Alberto Villanueva; Matthias Gross; Sven Diederichs; Sonia Guil; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

Review 10.  Resistant mechanisms to BRAF inhibitors in melanoma.

Authors:  José Luís Manzano; Laura Layos; Cristina Bugés; María de Los Llanos Gil; Laia Vila; Eva Martínez-Balibrea; Anna Martínez-Cardús
Journal:  Ann Transl Med       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.